JNJ vs PFE
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | JNJ | PFE | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $270.24 | $28.07 | |
| Market cap as of 2026-08-24 | $651.3B | $160.0B | |
| P/E as of 2026-08-24 | 29.93 | 35.19 | JNJ lower |
| PEG as of 2026-08-24 | 3.39 | -2.72 | PFE lower |
| Net margin as of 2026-08-24 | +21.5% | +6.8% | JNJ higher |
| Gross margin as of 2026-08-24 | +68.0% | +74.7% | PFE higher |
| Operating margin as of 2026-08-24 | +25.7% | +6.8% | JNJ higher |
| ROE as of 2026-08-24 | +25.7% | +4.9% | JNJ higher |
| ROA as of 2026-08-24 | +10.6% | +2.1% | JNJ higher |
| Debt / equity as of 2026-08-24 | 0.58 | 0.74 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.1% | -0.2% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | -14.8% | JNJ higher |
| Dividend yield as of 2026-08-24 | +3.1% | +5.4% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.20 | 0.28 | |
| 1-year return as of 2026-08-21 close | +51.0% | +9.1% | JNJ higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.